Stimulants A wealth of evidence supports the use of stimulants in the treatment of ADHD in children. According to the evidence-based clinical practice guideline for outpatient evaluation and management of ADHD produced by the Cincinnati Children’s Hospital Medical Center, stimulants are first-line therapy in treatment plans requiring medications in children with ADHD. Stimulants approved for [...]

Introduction For many years, attention-deficit/hyperactivity disorder (ADHD) was considered a neuropsychological condition occurring strictly during childhood and adolescence. However, approximately 30% to 70% of children with ADHD continue to have symptoms into adulthood. The estimated U.S. prevalence of adult ADHD is 1% to 7%. In the last few years, the manifestation of the condition in [...]

Speaker: Gregory Krauss, MD, Associate Professor of Neurology, Department of Neurology, Johns Hopkins Hospital Epilepsy Center, Baltimore, Maryland Intravenous (IV) lacosamide, a new chemical entity being developed as a formulation for the treatment of partial-onset seizures, was observed to be safe, well tolerated, and effective as a short-term replacement for oral lacosamide.

Speaker: Ketil B. Olsen, MD, Professor of Neurology, Department of Neurology, Division of Clinical Neuroscience, Rikshospitalet-Radiumhospitalet, University of Oslo, Oslo, Norway IV valproate (Depakene, Abbott), a well-known agent that inhibits GABA transaminase, was effective and safe for patients with status epilepticus and serial attacks that were resistant to benzodiazepine therapy.

Speaker: Iratxe Maestro, MD, Neurologist, Department of Neurology, Hospital Clinic, Barcelona, Spain Pregabalin generic (Drug Lyrica, Pfizer), an antiepileptic drug, has proved effective and well tolerated when used in everyday clinical practice as adjunctive therapy in patients with refractory epilepsy. This agent was introduced in Europe in February 2005. It acts as a ligand for [...]

Levetiracetam as First-Line Therapy in Older Epileptic Patients Speaker: Nicola Paciello, MD, Neurologist, Neuroscience Department, Neurology Unit, San Carlo Hospital, Potenza, Italy Although the efficacy of levetiracetam (Keppra, UCB Pharma) and carbamazepine drug (Canadian Tegretol, Novartis), which are both used as monotherapy, were comparable in preventing seizures in elderly patients with epilepsy, the retention of [...]

Presenter: Neil Shah, MD, PhD, University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California The prognosis is poor for patients with chronic myeloid leukemia (CML) who are receiving imatinib (Gleevec, STI-571, Novartis) when their disease progresses to accelerated phase or blast-phase CML. In the START-R trial of CML, which compared imatinib doses, increased [...]